Ociperlimab represents a very important development in treating self-immune disorders. The experimental antibody therapy targets neonatal Fc receptor gamma , a key molecule implicated in activating inflammatory responses. Initial clinical results indicate potential for diminishing symptoms across multiple conditions, such as SLE and intestinal cond